Crystallographic studies of intact and fully glycosylated HIV-1 gp120
完整和完全糖基化的 HIV-1 gp120 的晶体学研究
基本信息
- 批准号:8663835
- 负责人:
- 金额:$ 44.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-20 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntiviral AgentsBindingBiochemicalCCR5 geneCD4 AntigensCXCR4 geneCarbohydratesCell membraneCellsCharacteristicsChronicComplexCrystallizationDNA Sequence RearrangementDevelopmentEvolutionGlycoproteinsHIV Envelope Protein gp120HIV-1ImmuneInfectionKnowledgeLaboratoriesLeadLengthLigandsLightMediatingMembrane FusionMolecularPatientsPhasePolysaccharidesProcessProtein FragmentProteinsResearchResistanceResolutionSolutionsStructureTherapeuticTropismViralVirusbasechemokine receptorenv Gene Productsimprovedinsightneutralizing antibodynovelpublic health relevancereceptorreceptor bindingstructural biologytherapeutic vaccinevaccine development
项目摘要
DESCRIPTION (provided by applicant): HIV-1 infection begins with fusion of viral and target cell membranes. Viral attachment and membrane fusion are mediated by viral envelope spikes upon engagement with host cellular receptors. The mature envelope spikes contain three copies each of noncovalently-associated receptor-binding subunit gp120 and fusion subunit gp41. Despite considerable progress in our understanding of the structure of HIV-1 envelope glycoprotein over the last 15 years, we still do not have an atomic picture of the full-length and fully glycosylated gp120 due to enormous technical challenges associated with crystallographic studies of this protein, which is heavily coated with carbohydrates. Such a structure is, however, critical for a full understanding of gp120 function, as well as its interactions with various ligans, in particular, broadly neutralizing antibodies (bNAbs). Determination of an atomic structure of an intact HIV-1 gp120 will mark an important milestone in structural biology of HIV-1 entry, and may also guide development of antiviral therapeutics and vaccines. We have obtained diffracting crystals of a full-length and fully glycosylated HIV-1 gp120. In this application, we propose to determine crystal structures of the intact and glycosylated HIV-1 gp120 in complex with several neutralizing antibodies. We hypothesize that high-solution crystal structures of the unaltered HIV-1 gp120 will provide novel mechanistic insights into gp120 function, antibody neutralization and immune evasion. We will pursue the following specific aims: 1) We will determine the crystal structure of an intact, fully-glycosylated HIV-1 gp120; 2) We will determine the crystal structure of intact gp120 in complex with 2 domain CD4 and an anti-CD4 antibody ibalizumab; 3) We will determine crystal structures of HIV-1 gp120s with distinct characteristics.
描述(由申请方提供):HIV-1感染始于病毒和靶细胞膜的融合。病毒附着和膜融合由病毒包膜刺突在与宿主细胞受体接合时介导。成熟的包膜刺突包含三个拷贝的非共价相关受体结合亚基gp 120和融合亚基gp 41。尽管在过去的15年里,我们对HIV-1包膜糖蛋白结构的理解取得了相当大的进展,但由于与这种蛋白质的晶体学研究相关的巨大技术挑战,我们仍然没有全长和完全糖基化的gp 120的原子图像,这种蛋白质被大量的碳水化合物包裹。然而,这样的结构对于全面理解gp 120功能以及其与各种配体,特别是广泛中和抗体(bNAb)的相互作用至关重要。确定完整HIV-1 gp 120的原子结构将标志着HIV-1进入结构生物学的重要里程碑,也可能指导抗病毒治疗和疫苗的开发。我们已经获得了全长和完全糖基化的HIV-1 gp 120的衍射晶体。在本申请中,我们建议确定与几种中和抗体复合的完整和糖基化的HIV-1 gp 120的晶体结构。我们假设,未改变的HIV-1 gp 120的高溶液晶体结构将为gp 120功能,抗体中和和免疫逃避提供新的机制见解。我们将追求以下具体目标:1)我们将确定完整的、完全糖基化的HIV-1 gp 120的晶体结构; 2)我们将确定完整的gp 120与2结构域CD 4和抗CD 4抗体ibalizumab复合物的晶体结构; 3)我们将确定具有不同特征的HIV-1 gp 120的晶体结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bing Chen其他文献
Bing Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bing Chen', 18)}}的其他基金
Exploring the membrane-related components of HIV-1 Env for immunogen design
探索 HIV-1 Env 的膜相关成分以进行免疫原设计
- 批准号:
10762577 - 财政年份:2023
- 资助金额:
$ 44.15万 - 项目类别:
Structure of HIV-1 envelope spike in the context of membrane
膜背景下 HIV-1 包膜刺突的结构
- 批准号:
10322988 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Structure of HIV-1 envelope spike in the context of membrane
膜背景下 HIV-1 包膜刺突的结构
- 批准号:
10538590 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Structure of the full-length spike protein of SARS-CoV-2 in the context of membrane
膜背景下 SARS-CoV-2 全长刺突蛋白的结构
- 批准号:
10117733 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Structure of HIV-1 envelope spike in the context of membrane
膜背景下 HIV-1 包膜刺突的结构
- 批准号:
10013609 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Structural Basis of Coreceptor Recognition by HIV-1 Envelope Spike
HIV-1 包膜尖峰识别辅助受体的结构基础
- 批准号:
9906847 - 财政年份:2018
- 资助金额:
$ 44.15万 - 项目类别:
Structural Basis of Coreceptor Recognition by HIV-1 Envelope Spike
HIV-1 包膜尖峰识别辅助受体的结构基础
- 批准号:
10390469 - 财政年份:2018
- 资助金额:
$ 44.15万 - 项目类别:
Novel therapeutics targeting the membrane proximal external region of HIV-1 Env
针对 HIV-1 包膜近膜外部区域的新型疗法
- 批准号:
9513722 - 财政年份:2017
- 资助金额:
$ 44.15万 - 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:
10653205 - 财政年份:2016
- 资助金额:
$ 44.15万 - 项目类别:
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
HIV-1 Env 刺突膜相互作用域的结构功能研究
- 批准号:
10449192 - 财政年份:2016
- 资助金额:
$ 44.15万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 44.15万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 44.15万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 44.15万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 44.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 44.15万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 44.15万 - 项目类别: